Stem Cell Transplant Clinical Trial
Official title:
A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression
Verified date | July 2018 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
- Gardasil , a recently approved vaccine for the sexually transmitted human papillomavirus
(HPV), provides immunity to four types of HPV that are associated with genital warts and
cervical, vaginal, and vulvar precancer and cancer. The vaccine has been shown to be
highly effective in preventing infection with these HPV types and was approved for use
by the Food and Drug Administration.
- More research is needed about the vaccine s ability to induce immunity in individuals
with suppressed immune systems, such as those who have had other kinds of cancer
treatment such as stem cell transplant. Genital warts, precancer, and cancer have been
reported as a late complication after stem cell transplant. Researchers are interested
in determining whether the HPV vaccine is safe to give and able to induce immunity in
female stem cell transplant recipients, their female donors, and healthy female
volunteers.
Objectives:
- To assess the safety and immune response of the HPV vaccine in female recipients of stem
cell transplants who are either off or on stable doses of immunosuppression.
Eligibility:
- Females between 18 and 50 years of age who have had allogenic stem cell transplants.
- Healthy female volunteers, including stem cell donors, are also eligible for this study.
Design:
- Participants will be screened with a physical examination, blood and urine tests, and
saliva samples, and will be asked to complete a sexual quality of life questionnaire.
- Sexually active participants will also have a routine gynecologic evaluation.
- Participants will receive three HPV vaccinations according to the standard vaccination
schedule (with the second and third following 2 and 6 months after the first).
Participants will record their daily temperature and any reactions to the vaccine on a
vaccine report card for 1 week after each vaccination.
- Participants will have clinic visits for further testing 2, 6, 7, and 12 months after
receiving the first HPV vaccine.
Status | Completed |
Enrollment | 64 |
Est. completion date | July 19, 2016 |
Est. primary completion date | July 19, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility |
- INCLUSION CRITERIA: Female stem cell transplant recipient at least 90 days post stem cell transplant OR Female stem cell transplant recipient at least 90 days post HSCT and on immunosuppression OR The matched female stem cell transplant donor for an included stem cell transplant recipient OR Healthy female subject Age greater than or equal to 18 years and less than or equal to 50 years EXCLUSION CRITERIA: Vaccine Recipient: Obvious HPV condyloma or obvious severe dysplasia (greater than or equal to CIN II) warranting treatment History of severe adverse reaction to any components (yeast, eggs, monosodium glutamate or neomycin) of the quadrivalent HPV vaccine. Untreated or persistent life-threatening infections not controlled by current treatment Uncontrolled chronic GVHD i.e. highly active eGVHD requiring immediate intervention Pregnant or breast feeding or unwilling to be abstinent or practice effective contraception during the study period (note: patients who have been rendered infertile with total body irradiation are eligible) Enrollment in another vaccine clinical trial during the study period Enrollment of healthy volunteer in a drug clinical trial during the study period Inability to comprehend the investigational nature of the study and provide informed consent<TAB> Prior Gardasil or other HPV vaccination Persistent or recurrent malignancy |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004 Dec;31(12):748-52. — View Citation
Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-63. Review. — View Citation
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Subjects Who Developed Antibody Response to the Vaccine. | The percentage of subjects who developed antibody response to the quadrivalent HPV (qHPV) vaccine (HPV - 6/ - 11/ - 16/ - 18). Anti-HPV-6/11/16/18-specific antibody responses using L1 Virus Like Particle (VLP) ELISA were measured in serum. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641378 -
Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Recruiting |
NCT03562065 -
Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord
|
Phase 1/Phase 2 | |
Completed |
NCT01468935 -
Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning
|
||
Active, not recruiting |
NCT03938324 -
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
|
N/A | |
Completed |
NCT04219657 -
Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application
|
Phase 1 | |
Not yet recruiting |
NCT03259217 -
Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers
|
Phase 1 | |
Recruiting |
NCT01189786 -
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
|
N/A | |
Recruiting |
NCT04610359 -
Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis
|
Phase 1 | |
Completed |
NCT05712148 -
Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Recruiting |
NCT05515497 -
BMT4me: Post-HSCT Medication Adherence mHealth App
|
N/A | |
Completed |
NCT01984671 -
Mobile Pain Coping Skills Training for Stem Cell Transplant Patients
|
N/A | |
Not yet recruiting |
NCT06075927 -
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT03440775 -
Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients
|
N/A | |
Recruiting |
NCT02652052 -
Hematopoietic Stem Cell Transplant Survivors Study
|
N/A | |
Not yet recruiting |
NCT04922970 -
Strength Training as Prevention and Treatment of Late Effects in Long-term Survivors of Pediatric HSCT.
|
N/A | |
Completed |
NCT04041219 -
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
|
Phase 4 | |
Completed |
NCT00656058 -
Montelukast to Treat Bronchiolitis Obliterans
|
Phase 2 | |
Recruiting |
NCT04375579 -
Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
||
Completed |
NCT03859765 -
In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients
|
N/A |